CN113244170A - Aztreonam injection preparation and preparation method thereof - Google Patents
Aztreonam injection preparation and preparation method thereof Download PDFInfo
- Publication number
- CN113244170A CN113244170A CN202110644695.7A CN202110644695A CN113244170A CN 113244170 A CN113244170 A CN 113244170A CN 202110644695 A CN202110644695 A CN 202110644695A CN 113244170 A CN113244170 A CN 113244170A
- Authority
- CN
- China
- Prior art keywords
- aztreonam
- beta
- arginine
- parts
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Abstract
The invention belongs to the technical field of biological medicines, and particularly relates to an aztreonam injection and a preparation method thereof, wherein the aztreonam injection is prepared from the following raw materials in parts by weight: 1 part of beta-aztreonam, 0.55-0.65 part of L-arginine, 40-60 parts of sorbitol, 0.7-1.2 parts of antioxidant and 1.7-2.1 parts of hydroxypropyl-beta-cyclodextrin. The preparation process is simple and has good stability; the raw material contains L-arginine, so that the ring opening of a beta-aztreonam compound is inhibited to form ring-opening impurities, and the stability of the mixture is improved; the beta-aztreonam is dissolved in the sorbitol, so that the solubility of the beta-aztreonam is increased, and the dosage of L-arginine is reduced; the antioxidant is added, and hydroxypropyl-beta-cyclodextrin is utilized for inclusion, so that the stability of the aztreonam injection preparation is further improved.
Description
Technical Field
The invention belongs to the technical field of biological medicines, and particularly relates to an aztreonam injection preparation and a preparation method thereof.
Background
Aztreonam, which was originally developed by the american schnobel corporation and first marketed in italy in 1984, is the first monocyclic beta-lactam antibiotic to be used clinically, has a high antibacterial activity against most aerobic gram-negative bacteria, including escherichia coli, klebsiella pneumoniae and enterobacteriaceae such as aketobacter, aerobacter, clodinierella, proteus, serratia, citrobacter, shigella, and the like, and also has a good antibacterial activity against pseudomonas aeruginosa, gonococcus, diplococcus meningitidis, and the like.
Aztreonam has various crystal structure forms, and is divided into a, beta, gamma, delta and other forms, wherein the a form has high solubility in water, is easy to absorb moisture, has poor fluidity and poor storage stability, and is not used for preparing a preparation. The beta-type aztreonam is not easy to absorb moisture, has good fluidity and better solid stability, so the medicinal use is generally beta type. However, the solubility of the beta-type aztreonam in water is low, the dissolution speed is slow, and in order to ensure the solubility and the dissolution speed, the addition of a certain proportion of arginine to the aztreonam is extremely necessary in practical situations.
The existing aztreonam for injection in the market at present is mainly a mixture of aztreonam and L-arginine, the two components of aztreonam and L-arginine are easy to be layered in the vibration processes of production, transportation, storage and the like to cause uneven mixing, in addition, the stability of the existing aztreonam preparation is poor, related substances are increased greatly after long-term storage, and the quality requirement in the valid period can not be met. It is urgently needed to provide aztreonam pharmaceutical preparation with good stability and suitable for clinical use.
Disclosure of Invention
The invention aims to solve the problems and provides an aztreonam injection preparation and a preparation method thereof, which have good stability and simple preparation process.
According to the technical scheme of the invention, the aztreonam injection is prepared from the following raw materials in parts by weight: 1 part of beta-aztreonam, 0.55-0.65 part of L-arginine, 40-60 parts of sorbitol, 0.7-1.2 parts of antioxidant and 1.7-2.1 parts of hydroxypropyl-beta-cyclodextrin.
Preferably, the composition is prepared from the following raw materials in parts by weight: 1 part of beta-aztreonam, 0.58-0.61 part of L-arginine, 45-55 parts of sorbitol, 0.9-1.1 parts of antioxidant and 1.7-1.9 parts of hydroxypropyl-beta-cyclodextrin.
Further, the antioxidant is ascorbic acid and/or vitamin C.
Another aspect of the present invention provides a method for preparing any one of the aztreonam injection preparations, comprising the steps of:
s1: dissolving beta-aztreonam in sorbitol to prepare aztreonam sorbitol solution;
s2: adding an L-arginine aqueous solution, uniformly mixing and preserving heat;
s3: adding an antioxidant and hydroxypropyl-beta-cyclodextrin, stirring for reaction, adding water for injection to dilute to a required mass concentration, filtering with a 0.22 mu m filter element, filling into a penicillin bottle, and freeze-drying to obtain the aztreonam injection preparation.
Further, in the step S2, the mass fraction of the L-arginine aqueous solution is 10-20%.
Further, in the step S2, the L-arginine aqueous solution is added dropwise.
Further, in the step S2, the temperature is kept at 50-60 ℃ for 40-50 min.
Preferably, the temperature of the incubation is 55 ℃.
Further, in the step S3, the stirring reaction time is 2-3 h.
Further, in step S3, the 0.22 μm filter element is filtered by a 0.45 μm filter element before being filtered. And hierarchical filtering is formed, so that the filtering effect and efficiency are ensured.
Compared with the prior art, the technical scheme of the invention has the following advantages: the preparation process is simple and the stability is good; the raw material contains L-arginine, so that the ring opening of a beta-aztreonam compound is inhibited to form ring-opening impurities, and the stability of the mixture is improved; the beta-aztreonam is dissolved in the sorbitol, so that the solubility of the beta-aztreonam is increased, and the dosage of L-arginine is reduced; the antioxidant is added, and hydroxypropyl-beta-cyclodextrin is utilized for inclusion, so that the stability of the aztreonam injection preparation is further improved.
Detailed Description
The present invention is further described below in conjunction with specific examples to enable those skilled in the art to better understand the present invention and to practice it, but the examples are not intended to limit the present invention.
Example 1
Beta-aztreonam 100g
L-arginine 55g
Sorbitol 2600mL
Ascorbic acid 70g
170g of hydroxypropyl-beta-cyclodextrin
The preparation method comprises the following steps:
s1: dissolving 100g of beta-aztreonam in 2600mL of sorbitol to prepare an aztreonam sorbitol solution;
s2: adding 55g of L-arginine into water for injection to prepare an L-arginine aqueous solution with the mass fraction of 10%;
s3: adding the L-arginine aqueous solution obtained in the step S2 into the aztreonam sorbitol solution obtained in the step S1, uniformly mixing, and preserving heat for 50min at the temperature of 50 ℃;
s4: adding 70g of ascorbic acid and 170g of hydroxypropyl-beta-cyclodextrin, stirring for reacting for 2h, adding water for injection to dilute to a required mass concentration, filtering by a 0.45 mu m filter element, filtering by a 0.22 mu m filter element, filling into a penicillin bottle, and freeze-drying to obtain the aztreonam injection preparation.
The obtained aztreonam injection preparation is placed under the conditions of illumination of 6000Lx, temperature of 60 ℃ and relative humidity of 75% for 10-20 days, the solution is observed to be clear and colorless, and the detection result of insoluble particles shows that the total impurities are 0.45%.
Example 2
Beta-aztreonam 100g
58g of L-arginine
Sorbitol 3000mL
Ascorbic acid 90g
Hydroxypropyl-beta-cyclodextrin 180g
The preparation method comprises the following steps:
s1: dissolving 100 beta-aztreonam in 3000mL of sorbitol to prepare an aztreonam sorbitol solution;
s2: adding 58g L-arginine into water for injection to prepare an L-arginine aqueous solution with the mass fraction of 15%;
s3: adding the L-arginine aqueous solution obtained in the step S2 into the aztreonam sorbitol solution obtained in the step S1, uniformly mixing, and preserving heat for 45min at the temperature of 55 ℃;
s4: adding 90g of ascorbic acid and 180g of hydroxypropyl-beta-cyclodextrin, stirring for reacting for 2 hours, adding water for injection to dilute to a required mass concentration, filtering by a 0.45 mu m filter element, filtering by a 0.22 mu m filter element, filling into a penicillin bottle, and freeze-drying to obtain the aztreonam injection preparation.
The obtained aztreonam injection preparation is placed under the conditions of illumination of 6000Lx, temperature of 60 ℃ and relative humidity of 75% for 10-20 days, the solution is observed to be clear and colorless, and the detection result of insoluble particles shows that the total impurities are 0.34%.
Example 3
Beta-aztreonam 100g
L-arginine 61g
3700mL sorbitol
Ascorbic acid 110g
Hydroxypropyl-beta-cyclodextrin 190g
The preparation method comprises the following steps:
s1: dissolving 100g of beta-aztreonam in sorbitol to prepare aztreonam sorbitol solution;
s2: adding 61g L-arginine into water for injection to prepare an L-arginine aqueous solution with the mass fraction of 20%;
s3: adding the L-arginine aqueous solution obtained in the step S2 into the aztreonam sorbitol solution obtained in the step S1, uniformly mixing, and preserving heat for 55min at the temperature of 60 ℃;
s4: adding 110g of ascorbic acid and 190g of hydroxypropyl-beta-cyclodextrin, stirring for reacting for 3h, adding water for injection to dilute to a required mass concentration, filtering by a 0.45 mu m filter element, filtering by a 0.22 mu m filter element, filling into a penicillin bottle, and freeze-drying to obtain the aztreonam injection preparation.
The obtained aztreonam injection preparation is placed under the conditions of illumination of 6000Lx, temperature of 60 ℃ and relative humidity of 75% for 10-20 days, the solution is observed to be clear and colorless, and the detection result of insoluble particles shows that the total impurities are 0.36%.
Example 4
Beta-aztreonam 100g
L-arginine 65g
Sorbitol 4000mL
Ascorbic acid 120g
Hydroxypropyl-beta-cyclodextrin 210g
The preparation method comprises the following steps:
s1: dissolving 100g of beta-aztreonam in sorbitol to prepare aztreonam sorbitol solution;
s2: adding 65g L-arginine into water for injection to prepare an L-arginine aqueous solution with the mass fraction of 10-20%;
s3: adding the L-arginine aqueous solution obtained in the step S2 into the aztreonam sorbitol solution obtained in the step S1, uniformly mixing, and preserving heat for 40-50min at the temperature of 60 ℃;
s4: adding 120g of ascorbic acid and 210g of hydroxypropyl-beta-cyclodextrin, stirring for reacting for 2.5h, adding water for injection to dilute to the required mass concentration, filtering by a 0.45 mu m filter element, filtering by a 0.22 mu m filter element, filling into a penicillin bottle, and freeze-drying to obtain the aztreonam injection preparation.
The obtained aztreonam injection preparation is placed under the conditions of illumination of 6000Lx, temperature of 60 ℃ and relative humidity of 75% for 10-20 days, the solution is observed to be clear and colorless, and the detection result of insoluble particles shows that the total impurities are 0.41%.
Example 5
Beta-aztreonam 100g
L-arginine 61g
3700mL sorbitol
Vitamin C110 g
Hydroxypropyl-beta-cyclodextrin 190g
The preparation method comprises the following steps:
s1: dissolving 100g of beta-aztreonam in sorbitol to prepare aztreonam sorbitol solution;
s2: adding 61g L-arginine into water for injection to prepare an L-arginine aqueous solution with the mass fraction of 14%;
s3: adding the L-arginine aqueous solution obtained in the step S2 into the aztreonam sorbitol solution obtained in the step S1, uniformly mixing, and preserving heat for 45min at the temperature of 55 ℃;
s4: adding 110g of vitamin C and 190g of hydroxypropyl-beta-cyclodextrin, stirring for reacting for 2.5h, adding water for injection to dilute to the required mass concentration, filtering by a 0.45-micron filter element, filtering by a 0.22-micron filter element, filling into a penicillin bottle, and freeze-drying to obtain the aztreonam injection preparation.
The obtained aztreonam injection preparation is placed under the conditions of illumination of 6000Lx, temperature of 60 ℃ and relative humidity of 75% for 10-20 days, the solution is observed to be clear and colorless, and the detection result of insoluble particles shows that the total impurities are 0.37%.
Example 6
Beta-aztreonam 100g
L-arginine 61g
3700mL sorbitol
Ascorbic acid 50g
Vitamin C60 g
Hydroxypropyl-beta-cyclodextrin 190g
The preparation method comprises the following steps:
s1: dissolving 100g of beta-aztreonam in sorbitol to prepare aztreonam sorbitol solution;
s2: adding 61g L-arginine into water for injection to prepare an L-arginine aqueous solution with the mass fraction of 18%;
s3: adding the L-arginine aqueous solution obtained in the step S2 into the aztreonam sorbitol solution obtained in the step S1, uniformly mixing, and preserving the heat for 40min at the temperature of 60 ℃;
s4: adding 60g of vitamin C, 50g of ascorbic acid and 190g of hydroxypropyl-beta-cyclodextrin, stirring for reacting for 3h, adding water for injection to dilute to the required mass concentration, filtering by a 0.45-micron filter element, filtering by a 0.22-micron filter element, filling into a penicillin bottle, and freeze-drying to obtain the aztreonam injection preparation.
The obtained aztreonam injection preparation is placed under the conditions of illumination of 6000Lx, temperature of 60 ℃ and relative humidity of 75% for 10-20 days, the solution is observed to be clear and colorless, and the detection result of insoluble particles shows that the total impurities are 0.31%.
It should be understood that the above examples are only for clarity of illustration and are not intended to limit the embodiments. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. And are neither required nor exhaustive of all embodiments. And obvious variations or modifications of the invention may be made without departing from the spirit or scope of the invention.
Claims (10)
1. The aztreonam injection is characterized by being prepared from the following raw materials in parts by weight: 1 part of beta-aztreonam, 0.55-0.65 part of L-arginine, 40-60 parts of sorbitol, 0.7-1.2 parts of antioxidant and 1.7-2.1 parts of hydroxypropyl-beta-cyclodextrin.
2. The aztreonam injection preparation as claimed in claim 1, which is prepared from the following raw materials in parts by weight: 1 part of beta-aztreonam, 0.58-0.61 part of L-arginine, 45-55 parts of sorbitol, 0.9-1.1 parts of antioxidant and 1.7-1.9 parts of hydroxypropyl-beta-cyclodextrin.
3. The aztreonam injection formulation of claim 1, wherein the antioxidant is ascorbic acid and/or vitamin C.
4. A process for the preparation of an aztreonam injection formulation as defined in any one of claims 1 to 3, comprising the steps of:
s1: dissolving beta-aztreonam in sorbitol to prepare aztreonam sorbitol solution;
s2: adding an L-arginine aqueous solution, uniformly mixing and preserving heat;
s3: adding an antioxidant and hydroxypropyl-beta-cyclodextrin, stirring for reaction, adding water for injection to dilute to a required mass concentration, filtering with a 0.22 mu m filter element, filling into a penicillin bottle, and freeze-drying to obtain the aztreonam injection preparation.
5. The method according to claim 4, wherein the aqueous solution of L-arginine in step S2 contains 10 to 20% by mass of L-arginine.
6. The method according to claim 4, wherein the aqueous solution of L-arginine is added dropwise in step S2.
7. The method according to claim 4, wherein the temperature of the heat preservation in step S2 is 50-60 ℃ for 40-50 min.
8. The method according to claim 4, wherein the temperature for the heat-retaining in step S2 is 55 ℃.
9. The method of claim 4, wherein in step S3, the stirring reaction time is 2-3 h.
10. The method of claim 4, wherein in step S3, the 0.22 μm filter element is filtered through a 0.45 μm filter element before being filtered.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110644695.7A CN113244170A (en) | 2021-06-09 | 2021-06-09 | Aztreonam injection preparation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110644695.7A CN113244170A (en) | 2021-06-09 | 2021-06-09 | Aztreonam injection preparation and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113244170A true CN113244170A (en) | 2021-08-13 |
Family
ID=77187202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110644695.7A Pending CN113244170A (en) | 2021-06-09 | 2021-06-09 | Aztreonam injection preparation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113244170A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102145001A (en) * | 2011-01-24 | 2011-08-10 | 山东鲁抗立科药物化学有限公司 | Stable aztreonam composition and preparation method thereof |
-
2021
- 2021-06-09 CN CN202110644695.7A patent/CN113244170A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102145001A (en) * | 2011-01-24 | 2011-08-10 | 山东鲁抗立科药物化学有限公司 | Stable aztreonam composition and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110507616A (en) | A kind of aureomycin hydrochloride soluble powder and preparation method thereof | |
| CN106309448A (en) | Novel cefoperazone sodium and sulbactam sodium pharmaceutical composition for injection | |
| CN113244170A (en) | Aztreonam injection preparation and preparation method thereof | |
| CN110393721B (en) | Preparation method of cefotaxime sodium | |
| CN117379378A (en) | Compound amoxicillin soluble powder for livestock and preparation process thereof | |
| CN107261108B (en) | Long-acting amoxicillin and colistin sulfate injection and preparation method thereof | |
| CN102988286A (en) | Enrofloxacin injection | |
| CN117205151A (en) | Amikacin sulfate injection and preparation method thereof | |
| CN104800199A (en) | Calcium and zinc gluconate oral solution composition and preparation method thereof | |
| CN102145001B (en) | Stable aztreonam composition and preparation method thereof | |
| CN112089693A (en) | Penicillin composition for injection and preparation method thereof | |
| CN103142587B (en) | Amoxicillin sodium-potassium clavulanate pharmaceutical composition and preparation method thereof | |
| CN101548977B (en) | Composition of cefmetazole acid | |
| CN1943578A (en) | Medicinal composition containing ceftriaxone sodium and lidocaine hydrochloride injection | |
| CN1857225A (en) | Aseptic injection preparation containing ceftriaxone sodium and lidocaine hydrochloride | |
| CN113876722B (en) | Aztreonam for injection and preparation method thereof | |
| CN1813681A (en) | Sodium vitamin C powder for injection and its preparing method | |
| CN107661507A (en) | Enteric long-acting composite amoxicillin powder for animals and preparation method thereof | |
| CN1813680A (en) | Isepamicin sulfate powder for injection and its preparing method | |
| CN1227488A (en) | Improved method for preparing potassim clavulanate | |
| CN110893232A (en) | Cefoperazone sodium and sulbactam sodium powder injection for injection and preparation method thereof | |
| CN103142510A (en) | Injection containing moxifloxacin hydrochloride composition | |
| CN117323301B (en) | High-quality cefotaxime sodium preparation for injection and preparation method thereof | |
| CN117618363A (en) | Cefmetazole sodium freeze-dried powder injection for injection | |
| US4500516A (en) | Antibacterial pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210813 |
|
| RJ01 | Rejection of invention patent application after publication |